
Research in an animal model has shown that pregnancy can increase accumulation and activation of cells and functions associated with ectopic lymphoid structures (ELS) in Sjögren’s syndrome.

Research in an animal model has shown that pregnancy can increase accumulation and activation of cells and functions associated with ectopic lymphoid structures (ELS) in Sjögren’s syndrome.

Patients who have uveitis-glaucoma-hyphema (UGH) syndrome caused by the complications after implantation of an anterior chamber IOL fared worse with final visual outcomes than patients who also develop UGH but have other lenses implanted.

A systemic review of the peer-review literature has shown modern LASIK surgery is more effective and produces better outcomes than has been reported historically, said Kerry Solomon, MD.

“As we all know, errors in those initial measurements can have a negative effect on refractive outcomes,” Robert J. Cionni, MD, said. “Our goal is to get it right the first time.”

The Binkhorst Lecture and Medal have been conferred since 1975 on “an individual whose career has made significant contributions to the science and practice of ophthalmology and established that person among the world’s most prominent ophthalmologists.”

This year’s American Society of Cataract and Refractive Surgery (ASCRS) opening session zeroed in on one message: Members need to continue to be involved to ensure the society can meet members’ needs-from education to influence in the federal government.

Steven Dell, MD, and Steve Schallhorn, MD, compared the visual and subjective outcomes in patients who wear contact lenses with those who underwent wavefront-guided LASIK for the correction of myopia and astigmatism.

Though the main benefit of collagen corneal crosslinking is to stop progression of keratoconus, it is not the sole benefit, said Theo Seiler, MD, PhD (Greece) here during Cornea Day at ASCRS 2016.

Patient compliance (and non-compliance, as the case may be) is nothing new when discussing glaucoma. Nor are the multiple devices and systems previously developed or under investigation with the hope of improving compliance, said Richard Lewis, MD, speaking here at Glaucoma Day at ASCRS 2016.

Alex Huang, MD, PhD, is the winner of the Heidelberg Engineering Xtreme Research Award 2016 for his research on aqueous angiography and OCT structural analysis of outflow pathways.

Clinical researchers involved with ProgSTAR-believed to be the largest natural history study launched, to date, for Stargardt disease-are sharing interim findings during ARVO 2016.

Results from a series of preclinical studies are providing proof of principle that gene targeting using CRISPR-Cas9 genome-editing technology can prevent or treat glaucoma associated with mutations in the myocilin (MYOC) gene.

IOL implantation was associated with more inflammation and slightly more visual obscuration in 120 children age 2 or younger undergoing bilateral cataract surgery. However, the rate of glaucoma was similar compared with an aphakic group.

Patients with accommodating IOLs implanted using a femtosecond laser-assisted procedure or manual cataract removal had similar excellent visual outcomes.

For Joshua Mali, MD, the road to becoming an ophthalmologist started when he was just a teenager. When Dr. Mali was about 14 years old, his family took a trip to Nicaragua with Health for Humanity, and that was the beginning of what would be a decades-long service-oriented passion for Dr. Mali.

When the topic of IOL implantation is on the table, the age of the patient does make a difference, according to pediatric expert Courtney Kraus, MD, who spoke at the Wilmer Eye Institute’s 27th annual Current Concepts in Ophthalmology conference.

Every spring, ophthalmologists typically see a big influx of patients seeking relief from the itching and watery eyes that come with allergies. Learn the best methods to consider for helping your patients get through the allergy season.

Having a clear understanding of expectations from optical dispensary consumers is key to being able to resolve complaints.

Two clinicians explore why an optimal visual solution for patients may be using both a low-add multifocal and an extended-range-of-vision lens.

After childhood glaucoma has been treated, ophthalmologists expect to follow patients for years, monitoring them for a host of anatomical problems that can affect their vision.

Surgeons have several in-office treatments available for meibomian gland dysfunction.

Phakic IOLs are viable alternatives for treating high refractive errors.

The efficacy of a novel dry eye therapeutic may bring a valuable addition to the dry eye armamentarium with a rapid onset of action and better patient tolerability.

Implantation of the newest Implantable Collamer Lens phakic intraocular lenses (V4b and V4c) did not cause cataract formation in highly myopic patients.

For some time now, I find myself looking at my smartphone with a frequency that is frankly disconcerting. In committee meetings, lectures, sporting venues, social events, and other settings, my eyes and fingers find themselves gravitating to that little rectangular device. For some time now, I find myself looking at my smartphone with a frequency that is frankly disconcerting. In committee meetings, lectures, sporting venues, social events, and other settings, my eyes and fingers find themselves gravitating to that little rectangular device.

The advent of portable autorefractor technology may deliver autorefraction to populations that might not otherwise have any access to eye care.

Laser therapy that approaches bilateral glaucoma in a single treatment provides greater efficacy for the practice and more convenience for patients.

Giving pause to so-called conveniences that are offered for the sake of the patient may reveal just the opposite.

Cataract surgery in eyes with pseudoexfoliation syndrome is associated with increased intraoperative and postoperative risks. Strategies for improving outcomes include attention to IOL selection, and one surgeon describes why he is using a particular IOL.

A new, first-in-class, aldehyde-trap topical drop demonstrated rapid onset of action and sustained efficacy with an acceptable safety profile in a phase II clinical trial of patients with moderate-to-severe allergic conjunctivitis.